Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
On 12 January 2026, Smith+Nephew announced the acquisition of US-based Integrity Orthopaedics, an early-stage commercial developer of the Tendon Seam rotator cuff repair system, in a deal worth up to $450 million, including an initial $225 million in cash and performance-based payments over five years. The Tendon Seam technology, which received FDA 510(k) clearance in 2023, is designed to lower re-tear rates and simplify rotator cuff surgery in a US market estimated at $875 million, and will bolster Smith+Nephew’s already broad shoulder portfolio that includes the REGENETEN Bioinductive Implant, Q-FIX All-Suture Anchor and AETOS Shoulder System; financed from existing cash and expected to be accretive to trading profit margins by 2028 while keeping leverage below 2x EBITDA, the deal advances the company’s RISE growth strategy and strengthens its bid for global leadership in sports medicine shoulder repair.
The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue, operating through Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in 1856 in Hull, UK, it now operates in more than 100 countries, employs around 17,000 people and generated $5.8 billion in sales in 2024, with a strong presence in sports medicine and shoulder repair solutions and listings on both the London and New York stock exchanges.
Average Trading Volume: 586,933
Technical Sentiment Signal: Strong Buy
Current Market Cap: $14.34B
See more data about SNN stock on TipRanks’ Stock Analysis page.